Review summary
Teaching objective: Recognize pancreatic cancer in a young Black woman whose epigastric and back pain, weight loss, new diabetes and iron deficiency anemia could be put down to an ulcer or to stress, and care for it on the NCCN pancreatic adenocarcinoma guideline and the ASCO guidelines on potentially curable pancreatic cancer, palliative care and supportive care: pancreas-protocol CT and endoscopy at once; tissue by endoscopic ultrasound and biliary drainage before CA 19-9 is read; resectability staging and a multidisciplinary tumor board; germline genetic testing for every patient with pancreatic cancer and molecular profiling of the tumor; modified FOLFIRINOX before surgery for borderline resectable disease, with dose and support matched to her fitness; pancreaticoduodenectomy and chemotherapy after it; palliative care from the day of diagnosis; pain, nutrition and pancreatic enzyme replacement; diabetes caused by the pancreatic disease; venous thromboembolism risk; fertility and contraception; plain disclosure of the diagnosis and its prognosis; and a plan built around her wish to keep writing. Black Americans with pancreatic cancer are less often offered surgery and have worse survival, so each step is checked for delay.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| May 19, 1930 | Born in Chicago. | CLM-0001 |
| 1940 | The Supreme Court decides Hansberry v. Lee, the family's challenge to a restrictive covenant. | CLM-0002 |
| 1946 | Her father dies suddenly in Mexico. | CLM-0003 |
| June 1953 | Marries Robert Nemiroff, three years after leaving Wisconsin for New York. | CLM-0004 |
| March 11, 1959 | A Raisin in the Sun opens on Broadway, the first play by a Black woman produced there. | CLM-0005 |
| April 1963 | Fainting spells and attacks of nausea begin, first thought to be a duodenal ulcer. | CLM-0006 |
| By June 1963 | After a collapse in pain and a ten-day admission in which cancer is diagnosed (she is told of anemia and bleeding ulcers), an unsuccessful operation in New York. | CLM-0007, CLM-0008, CLM-0011 |
| August 1963 | Surgery at the Lahey Clinic at the New England Baptist Hospital in Boston. | CLM-0008 |
| 1964 | Gives the To Be Young, Gifted and Black speech on an afternoon out of hospital; The Sign in Sidney Brustein's Window opens in October. | CLM-0009 |
| January 12, 1965 | Dies of cancer at University Hospital in New York at 34. | CLM-0010, CLM-0011 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Lorraine Vivian Hansberry was born in Chicago on May 19, 1930, the youngest of four children of Carl Augustus Hansberry, a successful real estate broker who founded one of the city's first Black banks, and Nannie Louise (Perry) Hansberry, a schoolteacher. Her grandfather had been born enslaved. | confirmed | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports Lorraine Hansberry supports HISTMED Master Roster v3 context |
| D | In 1937 her family moved into a house in the all-white Washington Park subdivision of Woodlawn in defiance of a racially restrictive covenant. The resulting case, Hansberry v. Lee, was decided in the family's favor by the U.S. Supreme Court in 1940. Anchors the modern social history: a writer whose family fought housing segregation in court when she was a child. |
confirmed | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports |
| D | Her father died suddenly in Mexico in 1946 of a cerebral hemorrhage while planning to move the family there. Family history entry; no other family medical history was found in the cited sources. |
confirmed | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports |
| D | She enrolled at the University of Wisconsin in 1948, left in 1950 for New York, and wrote for the newspaper Freedom. In June 1953 she married Robert Nemiroff. Sources differ on when they divorced (1962 or 1964); they continued to work together. Her working life as a writer anchors the modern social history; the marriage is recorded only as the sources state it. |
confirmed | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports Lorraine Hansberry supports Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports |
| D | A Raisin in the Sun opened at the Ethel Barrymore Theatre on Broadway on March 11, 1959, the first play by a Black woman to be produced on Broadway. It won the New York Drama Critics' Circle Award; she was the first Black playwright and, at 29, the youngest American to win it. In 1962 she moved to Croton-on-Hudson, New York. Her documented career anchors the modern social history: a playwright at work on her next play. |
confirmed | Lorraine Hansberry supports Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports Lorraine Hansberry supports Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports |
| D | One account dates the start of her illness to April 1963, when she began to suffer from fainting spells and attacks of nausea; tests pointed at first to what was suspected to be a duodenal ulcer. The anchor for the modern presenting problem (epigastric pain, nausea and near-fainting with iron deficiency anemia). The month comes from one reference work only. |
probable | Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports |
| D | In 1963 she had an attack, collapsed in pain and was in hospital for ten days, during which doctors diagnosed cancer; she was told she had anemia and bleeding ulcers. The documented diagnosis to which the modern diagnosis is linked. That she was not told the diagnosis is the historical contrast with the modern episode, in which it is explained to her plainly. The month is not given. |
probable | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports |
| D | She had an unsuccessful operation in New York in June 1963 and surgery at the Lahey Clinic at the New England Baptist Hospital in Boston in August 1963; one account dates the operations to June 24 and August 2, and neither cured the cancer. Documented surgery after the index date; the modern episode's operation is synthetic. |
confirmed | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports Lorraine Hansberry supports |
| D | She kept writing and speaking through her illness. In May 1964, released from the hospital for the afternoon, she gave the speech that became known as To Be Young, Gifted and Black; in June she left her sickbed for a Town Hall debate; and in the fall she moved to a hotel near the rehearsals of The Sign in Sidney Brustein's Window, attending its opening night in October 1964. Her documented wish to keep working anchors the modern plan built around her writing. |
confirmed | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports |
| D | She died of cancer at University Hospital in New York on January 12, 1965, at 34; The Sign in Sidney Brustein's Window closed that night. Her funeral was held in Harlem on January 15. The documented death from cancer, to which the synthetic diagnosis is linked. History only, stated without detail. |
confirmed | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports Lorraine Hansberry supports Lorraine Hansberry supports |
| R | The primary site of her cancer is recorded differently: most reference works give pancreatic cancer; the PBS American Masters timeline gives cancer of the duodenum; and Women in World History describes colon cancer that had spread to the pancreas. One biography dates the diagnosis to 1964 rather than 1963. Retrospective; the sources disagree and no pathology was found. The modern episode uses a pancreatic head adenocarcinoma invading the duodenum, which is compatible with the accounts of pancreatic and duodenal cancer; this is a teaching choice, not a resolution of the historical question. |
disputed | Lorraine Hansberry supports Lorraine Hansberry supports Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | active | CLM-0006 |
| S | Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | active | CLM-0006 |
| S | New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | active | CLM-0006 |
| S | Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | both_with_link | CLM-0007, CLM-0010, CLM-0011 |
| S | Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | active | CLM-0007, CLM-0010 |
| S | Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | active | CLM-0007, CLM-0010 |
| S | Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | active | CLM-0007, CLM-0010 |
| S | Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | resolved | confirmed | active | CLM-0007, CLM-0010 |
| S | Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolved | resolved | confirmed | active | CLM-0007, CLM-0010 |
| S | Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons | active | confirmed | active | CLM-0007, CLM-0010 |
| S | After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetes | active | confirmed | active | CLM-0007, CLM-0010 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1963-04-20 | Hemoglobin [Mass/volume] in Blood | 9.1 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1963-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 74 fL (low) Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1963-04-20 | Leukocytes [#/volume] in Blood by Automated count | 7.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1963-04-20 | Platelets [#/volume] in Blood by Automated count | 388 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1963-04-20 | Ferritin [Mass/volume] in Serum or Plasma | 6 ng/mL (low) Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 1963-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1963-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1963-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1963-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M | 118 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1963-04-20 | Glucose [Mass/volume] in Serum or Plasma | 132 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1963-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 U/L (high) Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1963-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 U/L (high) Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1963-04-20 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 236 U/L (high) Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 1963-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1.6 mg/dL (high) Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1963-04-20 | Albumin [Mass/volume] in Serum or Plasma | 3.6 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1963-04-20 | Lipase [Enzymatic activity/volume] in Serum or Plasma | 52 U/L Reference 13-60 U/L |
http://loinc.org · 3040-3 |
| S | 1963-04-20 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.6% (high) Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes |
http://loinc.org · 4548-4 |
| S | 1963-04-20 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 1963-04-20 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | http://loinc.org · 72514-3 |
| S | 1963-05-04 | Hemoglobin [Mass/volume] in Blood | 10.4 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1963-05-04 | Leukocytes [#/volume] in Blood by Automated count | 7 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1963-05-04 | Neutrophils [#/volume] in Blood by Automated count | 4.6 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1963-05-04 | Platelets [#/volume] in Blood by Automated count | 366 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1963-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1963-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M | 119 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1963-05-04 | Glucose [Mass/volume] in Serum or Plasma | 141 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1963-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1963-05-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1963-05-04 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 U/L (high) Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 1963-05-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1963-05-04 | Albumin [Mass/volume] in Serum or Plasma | 3.5 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1963-05-04 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 486 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 1963-05-04 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 3.9 ng/mL (high) Reference Up to 3.0 ng/mL in non-smokers |
http://loinc.org · 2039-6 |
| S | 1963-05-04 | INR in Platelet poor plasma by Coagulation assay | 1 Reference 0.8-1.2 |
http://loinc.org · 6301-6 |
| S | 1963-05-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 1963-05-04 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | http://loinc.org · 70274-6 |
| S | 1963-05-04 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | http://loinc.org · 72514-3 |
| S | 1963-06-29 | Hemoglobin [Mass/volume] in Blood | 11.2 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1963-06-29 | Leukocytes [#/volume] in Blood by Automated count | 8.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1963-06-29 | Neutrophils [#/volume] in Blood by Automated count | 5.8 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1963-06-29 | Platelets [#/volume] in Blood by Automated count | 214 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1963-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1963-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M | 114 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1963-06-29 | Glucose [Mass/volume] in Serum or Plasma | 128 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1963-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1963-06-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1963-06-29 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 120 U/L (high) Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 1963-06-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1963-06-29 | Albumin [Mass/volume] in Serum or Plasma | 3.5 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1963-06-29 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 1963-06-29 | Ferritin [Mass/volume] in Serum or Plasma | 88 ng/mL Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 1963-06-29 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 210 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 1963-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | http://loinc.org · 44261-6 |
| S | 1963-06-29 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | http://loinc.org · 70274-6 |
| S | 1963-06-29 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | http://loinc.org · 72514-3 |
| S | 1963-07-16 | Hemoglobin [Mass/volume] in Blood | 11 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1963-07-16 | Leukocytes [#/volume] in Blood by Automated count | 6.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1963-07-16 | Neutrophils [#/volume] in Blood by Automated count | 4.1 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1963-07-16 | Platelets [#/volume] in Blood by Automated count | 188 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1963-07-16 | Sodium [Moles/volume] in Serum or Plasma | 134 mmol/L (low) Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1963-07-16 | Potassium [Moles/volume] in Serum or Plasma | 3.2 mmol/L (low) Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1963-07-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1963-07-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M | 83 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1963-07-16 | Glucose [Mass/volume] in Serum or Plasma | 118 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1963-07-16 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 mg/dL (low) Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 1963-08-10 | Hemoglobin [Mass/volume] in Blood | 10.9 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1963-08-10 | Leukocytes [#/volume] in Blood by Automated count | 7.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1963-08-10 | Neutrophils [#/volume] in Blood by Automated count | 4.9 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1963-08-10 | Platelets [#/volume] in Blood by Automated count | 176 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1963-08-10 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1963-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.1 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1963-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1963-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M | 107 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1963-08-10 | Glucose [Mass/volume] in Serum or Plasma | 124 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1963-08-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1963-08-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1963-08-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 U/L Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 1963-08-10 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1963-08-10 | Albumin [Mass/volume] in Serum or Plasma | 3.6 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1963-08-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 7% (high) Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes |
http://loinc.org · 4548-4 |
| S | 1963-08-10 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 41 U/mL (high) Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 1963-08-10 | INR in Platelet poor plasma by Coagulation assay | 1 Reference 0.8-1.2 |
http://loinc.org · 6301-6 |
| S | 1963-08-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 1963-08-10 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | http://loinc.org · 72514-3 |
| S | 1963-10-05 | Hemoglobin [Mass/volume] in Blood | 10.6 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1963-10-05 | Leukocytes [#/volume] in Blood by Automated count | 8.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1963-10-05 | Neutrophils [#/volume] in Blood by Automated count | 5.1 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1963-10-05 | Platelets [#/volume] in Blood by Automated count | 302 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1963-10-05 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1963-10-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1963-10-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.71 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1963-10-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M | 116 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1963-10-05 | Glucose [Mass/volume] in Serum or Plasma | 156 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1963-10-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1963-10-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1963-10-05 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 110 U/L (high) Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 1963-10-05 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1963-10-05 | Albumin [Mass/volume] in Serum or Plasma | 3.4 g/dL (low) Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1963-10-05 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 18 U/mL Reference <=35 U/mL |
http://loinc.org · 24108-3 |
| S | 1963-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 1963-10-05 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | http://loinc.org · 70274-6 |
| S | 1963-10-05 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | http://loinc.org · 72514-3 |
| S | 1963-10-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 1963-10-05 | Albumin/Creatinine [Mass Ratio] in Urine | 12 mg/g Reference <=30 mg/g |
http://loinc.org · 9318-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1963-04-20 | Body height | 163 cm | 8302-2 | S |
| 1963-04-20 | Body weight | 56.2 kg | 29463-7 | S |
| 1963-04-20 | Body mass index (BMI) [Ratio] | 21.2 kg/m2 | 39156-5 | S |
| 1963-04-20 | Systolic blood pressure | 104 mm[Hg] | 8480-6 | S |
| 1963-04-20 | Diastolic blood pressure | 66 mm[Hg] | 8462-4 | S |
| 1963-04-20 | Heart rate | 102 /min | 8867-4 | S |
| 1963-04-20 | Respiratory rate | 16 /min | 9279-1 | S |
| 1963-04-20 | Body temperature | 36.8 Cel | 8310-5 | S |
| 1963-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1963-05-04 | Body height | 163 cm | 8302-2 | S |
| 1963-05-04 | Body weight | 55.4 kg | 29463-7 | S |
| 1963-05-04 | Body mass index (BMI) [Ratio] | 20.9 kg/m2 | 39156-5 | S |
| 1963-05-04 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 1963-05-04 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1963-05-04 | Heart rate | 92 /min | 8867-4 | S |
| 1963-05-04 | Respiratory rate | 16 /min | 9279-1 | S |
| 1963-05-04 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1963-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1963-06-29 | Body height | 163 cm | 8302-2 | S |
| 1963-06-29 | Body weight | 54.8 kg | 29463-7 | S |
| 1963-06-29 | Body mass index (BMI) [Ratio] | 20.6 kg/m2 | 39156-5 | S |
| 1963-06-29 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 1963-06-29 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1963-06-29 | Heart rate | 84 /min | 8867-4 | S |
| 1963-06-29 | Respiratory rate | 16 /min | 9279-1 | S |
| 1963-06-29 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1963-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1963-08-10 | Body height | 163 cm | 8302-2 | S |
| 1963-08-10 | Body weight | 54.2 kg | 29463-7 | S |
| 1963-08-10 | Body mass index (BMI) [Ratio] | 20.4 kg/m2 | 39156-5 | S |
| 1963-08-10 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 1963-08-10 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 1963-08-10 | Heart rate | 80 /min | 8867-4 | S |
| 1963-08-10 | Respiratory rate | 16 /min | 9279-1 | S |
| 1963-08-10 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1963-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1963-10-05 | Body height | 163 cm | 8302-2 | S |
| 1963-10-05 | Body weight | 51.8 kg | 29463-7 | S |
| 1963-10-05 | Body mass index (BMI) [Ratio] | 19.5 kg/m2 | 39156-5 | S |
| 1963-10-05 | Systolic blood pressure | 106 mm[Hg] | 8480-6 | S |
| 1963-10-05 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1963-10-05 | Heart rate | 86 /min | 8867-4 | S |
| 1963-10-05 | Respiratory rate | 16 /min | 9279-1 | S |
| 1963-10-05 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1963-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1963-07-16 | Body height | 163 cm | 8302-2 | S |
| 1963-07-16 | Body weight | 53.6 kg | 29463-7 | S |
| 1963-07-16 | Body mass index (BMI) [Ratio] | 20.2 kg/m2 | 39156-5 | S |
| 1963-07-16 | Systolic blood pressure | 98 mm[Hg] | 8480-6 | S |
| 1963-07-16 | Diastolic blood pressure | 62 mm[Hg] | 8462-4 | S |
| 1963-07-16 | Heart rate | 104 /min | 8867-4 | S |
| 1963-07-16 | Respiratory rate | 16 /min | 9279-1 | S |
| 1963-07-16 | Body temperature | 37.1 Cel | 8310-5 | S |
| 1963-07-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1963-10-21 | Body height | 163 cm | 8302-2 | S |
| 1963-10-21 | Body weight | 52.4 kg | 29463-7 | S |
| 1963-10-21 | Body mass index (BMI) [Ratio] | 19.7 kg/m2 | 39156-5 | S |
| 1963-10-21 | Systolic blood pressure | 106 mm[Hg] | 8480-6 | S |
| 1963-10-21 | Diastolic blood pressure | 66 mm[Hg] | 8462-4 | S |
| 1963-10-21 | Heart rate | 84 /min | 8867-4 | S |
| 1963-10-21 | Respiratory rate | 14 /min | 9279-1 | S |
| 1963-10-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1963-10-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Playwright and essayist; writes at home most days and is finishing a new play, with readings and rehearsals planned; speaks at civil rights events
- S Lives alone in a small town on the Hudson River north of New York City and keeps a room in the city for theater work; separated, with no children; a close circle of friends and fellow writers; family in Chicago. No relative or friend is named or given a role in her care
- S Grew up in Chicago in a family that challenged housing segregation in court; she is alert to being dismissed in health care and wants to be told the truth plainly
- S Never smoker; alcohol a glass of wine some evenings; no drug use
- S Not pregnant and not trying to conceive; periods regular; uses condoms when sexually active
Functional status
- S Independent; working full days until the last two weeks, when tiredness and pain cut her writing to the mornings (ECOG performance status 1)
Mental status
- S Alert, articulate and exact; worried and tired; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast
- S Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart
- S Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain
- S Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone
- S Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack
- S Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles
- S Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5
- S Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6
- S Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles
- S Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus
- S Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected
- S Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea
- S Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle
- S Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed
- S Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery
- S Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days
- S Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery
- S Insulin glargine 100 units/mL pen, 8 units under the skin at night
- S Insulin glargine 100 units/mL pen, 10 units under the skin at night
- S Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snack
- S Irinotecan 20 mg/mL injection, 184 mg (120 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery
- S Leucovorin 10 mg/mL injection, 612 mg (400 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery
- S Fluorouracil 50 mg/mL injection, 3670 mg (2400 mg/m2) by continuous infusion over 46 hours from day 1 of each 14-day cycle, for six cycles after surgery
- S Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle after surgery
- S Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy after surgery
Procedures and immunizations
Procedures
- S Upper endoscopy with biopsy, under sedation: no gastric or duodenal ulcer; a friable, ulcerated mass on the medial wall of the second part of the duodenum next to the major papilla, oozing slowly; four biopsies taken; hemostasis with epinephrine injection
- S Pancreas-protocol CT of the abdomen and pelvis with contrast (arterial and portal venous phases), with CT of the chest: a 3.1 cm hypoattenuating mass in the head of the pancreas invading the duodenal wall; dilated common bile duct (13 mm) and pancreatic duct (5 mm); tumor contact with about 200 degrees of the superior mesenteric vein with short-segment narrowing that can be reconstructed; no contact with the superior mesenteric artery, celiac axis or common hepatic artery; no liver, peritoneal or lung lesion; no ascites
- S Endoscopic ultrasound with fine-needle biopsy of the pancreatic head mass (three passes with a 22-gauge biopsy needle): 3.2 cm hypoechoic mass invading the duodenum and abutting the portal confluence; no ascites; rapid on-site evaluation adequate; extra cores sent for tumor molecular profiling
- S ERCP in the same session with placement of a fully covered self-expanding metal stent (10 mm by 60 mm) across a distal common bile duct stricture; good drainage of bile
- S Pancreatic multidisciplinary tumor board (surgical oncology, medical oncology, radiation oncology, gastroenterology, radiology, pathology, palliative care, nurse navigator): borderline resectable pancreatic head adenocarcinoma (venous involvement); recommends chemotherapy before surgery with modified FOLFIRINOX, restaging, then resection if there is no progression
- S Advance care planning conversation, about 30 minutes
- S Genetic counseling before germline testing: three-generation pedigree, consent, and explanation of what a positive or negative result would mean for her and her blood relatives
- S Outpatient palliative care consultation, two days after the diagnosis visit: symptom review, a serious illness conversation about her hopes, worries and what matters most (her writing and a clear head), and a plan for pain, appetite and sleep alongside cancer treatment
- S Restaging pancreas-protocol CT of the abdomen and pelvis with contrast, with CT of the chest, after six cycles: pancreatic head mass smaller (2.1 cm from 3.1 cm); contact with the superior mesenteric vein reduced to about 150 degrees; no arterial contact; biliary stent in place; no liver, peritoneal or lung lesion
- S Open pylorus-preserving pancreaticoduodenectomy with segmental resection of the superior mesenteric vein and primary venous repair, and removal of the biliary stent: pathology ypT2N1 (2.3 cm residual adenocarcinoma; 2 of 18 lymph nodes involved; perineural invasion), all margins clear (R0), partial treatment response (CAP tumor regression score 2); nine days in hospital, with mild delayed gastric emptying that settled
Immunizations
- S 1959-09-12: Tdap vaccine
- S 1963-05-04: Pneumococcal conjugate vaccine (PCV20), before chemotherapy
- S 1963-05-04: Recombinant zoster vaccine, dose 1 of 2, before chemotherapy
- S 1963-06-29: Recombinant zoster vaccine, dose 2 of 2
- S 1963-10-21: Influenza vaccine, this season (inactivated)
- S 1963-10-21: COVID-19 mRNA vaccine, this season's formula
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
Family history
- D father: Died suddenly of a cerebral hemorrhage when she was sixteen; no cancer recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation | 1963-05-04 | completed | Endoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks |
| Germline genetic testing with counseling and tumor molecular profiling resulted before surgery | 1963-06-29 | completed | Germline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alteration |
| Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week | 1963-08-10 | completed | Six cycles; one dose reduction of irinotecan after diarrhea; CT shows a partial response |
| Resection with clear margins if restaging shows no progression | 1963-10-05 | completed | Pancreaticoduodenectomy with vein resection; margins clear (R0) |
| Pain 3 out of 10 or less with a clear head for writing | 1963-06-29 | completed | Pain 1 to 2 out of 10 on oxycodone 5 mg once or twice a day |
| Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support | 1963-08-10 | completed | Weight 54.2 kg before surgery, 2 percent below the weight at diagnosis |
| PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment | 1963-10-05 | completed | PHQ-9 between 6 and 8 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Medical oncology consultation within two weeks to review the endoscopy, CT and any biopsy with her and plan treatment if cancer is found | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016 |
| Urgent work-up of epigastric pain with weight loss, anemia and new diabetes: upper endoscopy within days, pancreas-protocol CT of the abdomen with CT of the chest, blood count, ferritin, liver tests, lipase and A1c; pantoprazole until the endoscopy; return at once for fresh black stools, fainting or yellow eyes | completed | GL-NCCN-PANC-2026, GL-NOEL-2019 |
| Intravenous iron for iron deficiency anemia from blood loss, with a blood count at each visit | completed | GL-NCCN-PANC-2026 |
| Tissue and staging: EUS-guided biopsy with extra cores for molecular profiling, biliary drainage with a metal stent, CA 19-9 after the bilirubin is normal, and review at the pancreatic tumor board | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016 |
| Germline genetic testing with counseling for every patient with pancreatic cancer, and tumor molecular profiling (including KRAS, BRCA1, BRCA2, PALB2, mismatch repair, NTRK and NRG1); cascade testing offered to blood relatives only if a germline variant is found | completed | GL-NCCN-PANC-2026, GL-ASCO-PANCGERM-2019, GL-ASCO-MPC-2020 |
| Modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 over 46 hours) every two weeks for six cycles (three months) before surgery through a port, with pegfilgrastim, olanzapine-based antiemetic prevention that spares dexamethasone because of her diabetes, loperamide for late diarrhea, and neuropathy checks; CA 19-9 every two cycles and restaging CT after four and six cycles; hepatitis B, hepatitis C and HIV screening and a pregnancy test first | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020 |
| Palliative care from the day of diagnosis, alongside cancer treatment: symptom control, a serious illness conversation, and planning that keeps her writing at the center; oxycodone 5 mg as needed with a bowel regimen, and EUS-guided celiac plexus neurolysis if pain becomes severe | completed | GL-ASCO-PALL-2024, GL-NCCN-PANC-2026 |
| Nutrition: dietitian review at each phase, pancrelipase with every meal and snack, small frequent meals, weight at every visit | completed | GL-NCCN-PANC-2026 |
| Diabetes due to pancreatic disease: home glucose checks, A1c every three months, glucose checks before each cycle; insulin rather than oral agents if treatment is needed after surgery; dilated eye examination and urine albumin-to-creatinine ratio at diagnosis | completed | GL-ADA-2026, GL-CMID-2026 |
| Venous thromboembolism: Khorana score recorded (3: pancreatic primary and hemoglobin below 10 g/dL); prophylactic apixaban offered once the duodenal bleeding has settled; enoxaparin for four weeks after surgery | completed | GL-ASCO-VTE-2023, GL-AVERT-2019 |
| Fertility and contraception: oncofertility counseling before chemotherapy, a pregnancy test before treatment, and effective non-estrogen contraception if she becomes sexually active during treatment | completed | GL-ASCO-FERT-2018 |
| Pylorus-preserving pancreaticoduodenectomy with resection of the involved segment of the superior mesenteric vein after restaging shows no progression | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016 |
| Chemotherapy after surgery to complete about six months of treatment: six cycles of fluorouracil, leucovorin and irinotecan every two weeks, without oxaliplatin because of neuropathy; insulin glargine adjusted to home glucose readings; apixaban prophylaxis resumed during chemotherapy; surveillance afterwards with history, examination, CA 19-9 and CT every three to six months for two years | completed | GL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-VTE-2023 |
| Distress and depression screening at each visit, plain explanations with written information, and support she chooses; she decides who is told and who receives each note | completed | GL-USPSTF-DEP-2023, GL-ASCO-PALL-2024 |
Planned encounters
- 1963-04-20 — Two months of epigastric and back pain, weight loss, black stools and near-fainting in a woman of 32: examination, blood tests, and urgent upper endoscopy and pancreas-protocol CT (ENC-001)
- 1963-05-04 — Diagnosis of pancreatic adenocarcinoma: tumor board plan, medical oncology consultation, genetic counseling, early palliative care, and planning of chemotherapy before surgery (ENC-002)
- 1963-06-29 — Day 1 of cycle 4 of modified FOLFIRINOX: toxicity review, genetic and tumor profiling results, thromboprophylaxis, nutrition and mood (ENC-003)
- 1963-07-16 — Same-day sick visit for diarrhea during chemotherapy (ENC-006, unscheduled)
- 1963-08-10 — After six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy (ENC-004)
- 1963-10-05 — Six weeks after pancreaticoduodenectomy: pathology, diabetes and enzyme replacement after surgery, and the plan for chemotherapy after surgery (ENC-005)
- 1963-10-21 — Periodic adult preventive visit during chemotherapy after surgery (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Medical Oncology (gastrointestinal) referral
- Medical Oncology (gastrointestinal) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Medical Oncology (gastrointestinal) referral (XML)
- Medical Oncology (gastrointestinal) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) | PBS / WNET | other |
| SRC-0002 | Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) | Encyclopedia.com (Charles Scribner's Sons) | other |
| SRC-0003 | Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) | Encyclopedia.com (Gale) | other |
| SRC-0004 | Lorraine Hansberry | Wikipedia | other |
| SRC-0005 | Lorraine Hansberry | Biography.com (A&E Television Networks) | other |
| SRC-0006 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the borderline resectable staging, the choice and dosing of modified FOLFIRINOX with a dexamethasone-sparing antiemetic plan, the reading of CA 19-9 after biliary drainage, the timing of apixaban after a bleeding duodenal tumor, insulin for diabetes after pancreaticoduodenectomy, and the chemotherapy after surgery without oxaliplatin. |
| provenance review | not_started | She died in 1965; the recent-death rule does not apply. Claims rest on the PBS American Masters timeline, two reference encyclopedias, Biography.com and Wikipedia. The primary site of her cancer is recorded as R because the sources disagree; everything clinical is synthetic. |
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative, friend or historical physician is given a role in the modern episode, and her private relationships are not used beyond the documented marriage. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.